Validation of SKY92 High and Low Risk Prognostication in a Retrospective, Multinational Cohort of 155 Non-Trial Multiple Myeloma Patients

Genetic hallmarks of multiple myeloma (MM) patients have been extensively studied based on biobanked samples that have been collected as part of clinical trials. For example, the gene expression profiling (GEP) based SKY92 signature, which identifies ∼15-20% of patients as high risk, has been independently validated in more than ten trials as a prognostic factor for progression free survival (PFS), and overall survival (OS). Limited evidence is available outside of trials, and here we present the first analysis of SKY92 and other markers on real-world MM data.